Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04826341 | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors | completed | Phase 1 / Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05512377 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 16 |
| Jul 21, 2026 |
| clinicaltrials |
| NCT05770310 | A Phase I Study Of JS015 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05740202 | A Trial of SHR-7367 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 22 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT05396300 | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 58 | Weijia Fang, MDOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06470763 | A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) | completed | Phase 1 / Phase 2 | 63 | Anaveon AGINDUSTRY | 7 | Jul 10, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05507736 | Feasibility and Safety of Acupuncture With Semi-Permanent Needles for the Prevention of Irinotecan-Associated Diarrhea in Pediatric Solid Tumors(AIP2021) | completed | N/A | 22 | Fundació Sant Joan de DéuOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04685473 | Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors | completed | Phase 1 | 24 | Taivex Therapeutics CorporationINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02710253 | Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy | completed | Phase 2 | 214 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT02088775 | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer | completed | N/A | 44 | Fox Chase Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04250155 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 195 | Genentech, Inc.INDUSTRY | 9 | Jul 2, 2026 | clinicaltrials |
| NCT06001684 | Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors | completed | Phase 1 | 19 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03239145 | Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | completed | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06209385 | A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors | completed | Phase 1 | 14 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04649385 | BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Jun 26, 2026 | clinicaltrials |
| NCT05763004 | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | completed | Phase 1 | 47 | ImmunOs Therapeutics AGINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05620472 | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05991349 | A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 36 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Jun 24, 2026 | clinicaltrials |
| NCT02792465 | A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06442891 | Self-Administered Relaxing Acupressure to Reduce Fatigue in Adolescent and Young Adult Cancer Survivors | completed | N/A | 42 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04471961 | Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia(ALADIN) | completed | N/A | 100 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06589414 | Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study(DAMeGe) | completed | N/A | 171 | Institut Claudius RegaudOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02987166 | HDCRT Plus Pembrolizumab in Advanced Malignancies(UVA-AM-001) | completed | Phase 1 | 21 | James Larner, MDOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05947474 | ORB-011 In Patients With Advanced Solid Tumors(ORB) | completed | Phase 1 | 55 | Orionis Biosciences IncINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06310655 | Online Proton Adaptive Radiotherapy(PARTy) | completed | N/A | 10 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06422520 | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 63 | BeOne MedicinesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07631611 | Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients | completed | — | 938 | Wenlong Zhong, MDOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06242691 | Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) | completed | Phase 1 / Phase 2 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jun 5, 2026 | clinicaltrials |
| NCT06602999 | Addressing the Nutritional Needs of Cancer Survivors With Nutrition Insecurity | completed | N/A | 40 | University of California, San FranciscoOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06235983 | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | Peter ZageOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04529122 | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test | completed | — | 7,864 | Hoffmann-La RocheINDUSTRY | 32 | May 27, 2026 | clinicaltrials |
| NCT06484595 | Clinical Trial Navigation to Increase Participation and Diversity in Cancer Clinical Trials(GUIDE) | completed | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04895592 | Radiosurgery Before Surgery for the Treatment of Brain Metastases | completed | Early Phase 1 | 26 | Emory UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07587996 | Exploratory Clinical Study of ¹⁷⁷Lu-CTR-FAPI in Patients With Metastatic Solid Tumors | completed | Early Phase 1 | 12 | Lanzhou University Second HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02797795 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | completed | Phase 1 | 78 | Neovia Oncology Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05038839 | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | completed | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05162755 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | completed | Phase 1 | 41 | Institut de Recherches Internationales ServierOTHER | 2 | May 12, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials